Earnings call transcript: STAAR Surgical beats Q1 2026 forecasts, stock rises

STAAR Surgical delivered a strong Q1 2026 beat, with EPS of $0.10 versus $0.05 expected and revenue of $93.5 million versus $78.74 million expected. Revenue rose 119.6% year over year, adjusted EBITDA swung to a $24.4 million profit from a $26.3 million loss, and shares gained 4.33% after hours to $28.21. Management pointed to China sales of $47.4 million, early EVO+ demand, and an optimistic 2026 outlook, but stopped short of formal guidance.

Analysis

This print is less about a clean earnings beat and more about a regime change in the operating model: STAAR is finally showing leverage in the quarter where China inventory normalization and Swiss manufacturing scale line up. The market is likely underestimating how much of the margin expansion is structural versus temporary; if the tariff-avoidance supply chain shift holds, gross margin can stay elevated even if top-line growth moderates. That makes the next few quarters more about whether management can sustain shipment cadence without re-creating channel noise than about whether demand itself is real.

The second-order winner is not just STAAR, but the whole lens-based refractive basket: ALC is the obvious relative loser because the evidence continues to point toward share migration away from laser-based procedures. If ICL adoption keeps expanding in the U.S. and China, the more important competitive casualty is the installed base economics of LASIK/PRK centers, which may have to discount harder to defend volume. That pressure could persist for several quarters, not days, because the workflow and surgeon-training switch into lens-based offerings is sticky once a practice decides to broaden its refractive menu.

The key risk is that the market may be extrapolating a normalized quarter into a normal growth trajectory before the seasonal test is complete. China is still the swing factor, and a flat-to-down summer season would compress the multiple quickly because the current move already prices in a lot of operational credibility. The bigger contrarian point: consensus is focused on revenue quality, but the real upside may come from mix — premium product adoption plus tariff-free Swiss supply can lift earnings faster than headline sales, even if ex-China growth only stays mid-single digit.

From here, the trade is to respect the trend but define the entry tightly. This is a momentum-plus-fundamentals setup, yet it is vulnerable to a guidance gap or a soft Q2 high season. The best asymmetry is likely in relative value versus medical device peers rather than outright chasing the stock after a strong run.

Key Decisions for Investors

• Long STAA on pullbacks toward the pre-earnings gap area; hold 4-8 weeks into Q2 seasonality, with upside if China demand confirms and margin expansion persists. Risk/reward is attractive only if entry is <5% above the last breakout level; above that, trim because the stock is already near highs.
• Pair trade: long STAA / short ALC for 1-3 months to express lens-based share migration versus laser-based procedural weakness. This is the cleaner fundamental relative-value expression if refractive demand stays stable and ICL adoption continues.
• Buy STAA call spreads 6-10 weeks out to capture a potential Q2 reaffirmation without paying full upside premium. Prefer a modest outlay structure because the main risk is not collapse in the business, but disappointment versus elevated expectations.
• If already long, hedge with a partial put spread into the next data point on China or any pre-close commentary. The stock’s current setup can de-rate fast if management stays noncommittal on seasonality and the street starts pricing a flat Q2.
• Watch for confirmation in ex-China growth and gross margin in the next print; if ex-China stays >5% and gross margin holds near current levels, add on strength. If either variable slips, treat the current move as crowded and reduce exposure.